None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

The magic mushroom compound psilocybin shows long-lasting antidepressant effects in a clinical trial, with patients reporting ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Deep transcranial magnetic stimulation was safe and effective in treating adolescents and young adults with major depressive ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Life Sciences (ATAI) stock rises as the company and Beckley Psytech said their psychedelic drug BPL-003 hit main goals in a ...

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...